Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
144 EUR | -0.07% |
|
+0.81% | +17.36% |
15.07. | AstraZeneca schließt $1,05 Milliarden Übernahme von Amolyt Pharma ab | MT |
15.07. | AstraZeneca PLC (LSE:AZN) hat die Übernahme von Amolyt Pharma SAS für $1,05 Milliarden abgeschlossen. | CI |
Kurzporträt
- Produktverkäufe (95,6%). Die Nettoumsätze verteilen sich auf die Behandlungsbereiche Onkologie (39,2%), Herz-Kreislauf-, Nieren- und Stoffwechselerkrankungen (24,2%), Atemwegs- und Autoimmunerkrankungen (13,9%) und Sonstige (22,7%; Entzündungskrankheiten, neurologische Erkrankungen, Magen-Darm- und Infektionskrankheiten);
- Einnahmen aus Kooperationen (4,4%).
Der Nettoumsatz verteilt sich geografisch wie folgt: Großbritannien (7,4%), Europa (21,2%), Amerika (45,3%) und Afrika-Asien-Australien (26,1%).
Mitarbeiterzahl: 89 900
Umsatz nach Geschäftsbereich
GBP in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Oncology
37,4
%
| 11 878 | 33,0 % | 13 793 | 37,4 % | +16.12% |
Cardiovascular, Renal and Metabolism
23,1
%
| 7 459 | 20,7 % | 8 515 | 23,1 % | +14.16% |
Rare Disease
16,9
%
| 5 726 | 15,9 % | 6 246 | 16,9 % | +9.08% |
Respiratory and Immunology
13,3
%
| 4 680 | 13,0 % | 4 913 | 13,3 % | +4.97% |
Alliance
3,1
%
| - | - | 1 149 | 3,1 % | - |
Other Medicines
2,6
%
| 1 319 | 3,7 % | 946 | 2,6 % | -28.29% |
Vaccines and Immune Therapies
2,2
%
| 3 845 | 10,7 % | 814 | 2,2 % | -78.83% |
Collaboration
1,3
%
| 1 098 | 3,1 % | 478 | 1,3 % | -56.50% |
Umsatz je Region
GBP in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
39,6
%
| 14 027 | 39,0 % | 14 578 | 39,6 % | +3.93% |
China
12,8
%
| 4 662 | 12,9 % | 4 724 | 12,8 % | +1.32% |
Japan
7,9
%
| 3 236 | 9,0 % | 2 928 | 7,9 % | -9.51% |
United Kingdom
7,4
%
| 2 530 | 7,0 % | 2 709 | 7,4 % | +7.07% |
Other Rest of Europe
6,8
%
| 2 197 | 6,1 % | 2 502 | 6,8 % | +13.89% |
Germany
4,6
%
| 1 544 | 4,3 % | 1 689 | 4,6 % | +9.36% |
Other Asia, Africa and Australasia
4,5
%
| 1 953 | 5,4 % | 1 645 | 4,5 % | -15.77% |
Sweden
3,7
%
| 1 397 | 3,9 % | 1 371 | 3,7 % | -1.89% |
Other Americas
3,7
%
| 954 | 2,6 % | 1 354 | 3,7 % | +41.94% |
France
2,5
%
| 899 | 2,5 % | 927 | 2,5 % | +3.12% |
Canada
2,1
%
| 947 | 2,6 % | 778 | 2,1 % | -17.82% |
Spain
1,8
%
| 599 | 1,7 % | 681 | 1,8 % | +13.73% |
Italy
1,8
%
| 597 | 1,7 % | 654 | 1,8 % | +9.61% |
Australia
0,9
%
| 464 | 1,3 % | 314 | 0,9 % | -32.32% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01.10.12 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01.08.21 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 01.08.23 |
Regina Danielson
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 01.01.20 |
Jeffrey Pott
CMP | Compliance Officer | - | 01.01.95 |
Chief Tech/Sci/R&D Officer | - | 18.05.23 | |
Pam Cheng
COO | Chief Operating Officer | 53 | 01.06.15 |
Iskra Reic
PRN | Corporate Officer/Principal | - | 01.01.01 |
Sjoerd Hubben
LAW | General Counsel | - | 01.03.16 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 66 | 01.10.17 |
Philip Broadley
BRD | Director/Board Member | 63 | 27.04.17 |
Director/Board Member | 68 | 01.04.99 | |
Marc Dunoyer
PRN | Corporate Officer/Principal | 71 | 01.06.13 |
Andreas Rummelt
BRD | Director/Board Member | 67 | 01.08.21 |
Michel Demaré
CHM | Chairman | 67 | 01.09.19 |
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01.10.12 |
Deborah DiSanzo
BRD | Director/Board Member | 64 | 01.12.17 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01.08.21 |
Shu Kam Mok
BRD | Director/Board Member | 63 | 01.01.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 1 550 268 075 | 1 498 125 092 ( 96,64 %) | 0 | 96,64 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
18 750 000 | 75,00% | 1 403 088 000 $ | |
35 043 624 | 9,89% | 938 450 028 $ | |
108 923 023 | 37,58% | 552 257 154 $ | |
NIOX GROUP PLC 16,76% | 71 065 878 | 16,76% | 61 626 197 $ |
CELLECTIS S.A. 22,19% | 16 000 000 | 22,19% | 28 362 720 $ |
INNATE PHARMA 9,25% | 7 485 500 | 9,25% | 15 034 327 $ |
44 803 | 3,39% | 439 562 $ | |
884 956 | 1,99% | 44 248 $ |
Unternehmenskontakt
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA, Cambridge
+44 20 3749 5000
http://www.astrazeneca.co.uk![Straße AstraZeneca PLC(ZEG)](https://cdn.zonebourse.com/static/address/439628.png)
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
R&Q Beta Co. Plc
![]() R&Q Beta Co. Plc Insurance Brokers/ServicesFinance R&Q Beta Co. Plc provides insurance services. The company was founded in 1994 and is headquartered in Cambridge, the United Kingdom. |
Insurance Brokers/Services
|
Alexion Pharmaceuticals, Inc. /New/
| |
Astrazeneca Treasury BV
| |
AstraZeneca AB
![]() AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. |
Miscellaneous Commercial Services
|
AstraZeneca Employee Share Trust Ltd.
![]() AstraZeneca Employee Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Employee Share Trust Ltd. is a British company that provides business support services. The company is located in the UK. |
Miscellaneous Commercial Services
|
AstraZeneca UK Ltd.
![]() AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. |
Miscellaneous Commercial Services
|
AstraZeneca Share Trust Ltd.
![]() AstraZeneca Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Share Trust Ltd. is a British company that provides business support services. The company is located in the UK. |
Miscellaneous Commercial Services
|
Astrazeneca Treasury Ltd.
![]() Astrazeneca Treasury Ltd. Financial ConglomeratesFinance Part of AstraZeneca PLC, AstraZeneca Treasury Ltd. functions as an investment holding British company. The company is based in Cambridge, UK. |
Financial Conglomerates
|
Astrazeneca Finance & Holdings, Inc.
![]() Astrazeneca Finance & Holdings, Inc. Financial ConglomeratesFinance Part of AstraZeneca PLC, Astrazeneca Finance & Holdings, Inc. is an investment holding American company. The company is located in the US. |
Financial Conglomerates
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
![Analystenschätzungen](/images/consensus_flch.gif)
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+63.05% | 856 Mrd. | |
+39.38% | 631 Mrd. | |
-3.75% | 359 Mrd. | |
+18.05% | 325 Mrd. | |
+9.14% | 297 Mrd. | |
+5.89% | 234 Mrd. | |
+16.84% | 226 Mrd. | |
+16.14% | 177 Mrd. | |
+2.05% | 165 Mrd. |
- Börse
- Aktien
- 886455 Aktie
- 886455 Aktie
- Unternehmen AstraZeneca PLC